10 Diwali Stock Picks 2026 | Muhurat Trading | MO Research

Summary

Motilal Oswal presents 10 stock ideas for Muhurat trading on 8 November 2026 and Samvat 2083, describing them as potential opportunities for the coming year. The figures below are brokerage estimates or targets quoted in the subtitles, not realized results. Several figures and names appear garbled in the auto-generated transcript; unclear items are flagged.

Stock Picks

1. Kotak Mahindra Bank — Banking

• Growth thesis: Loan-book growth of 1.5–2× nominal GDP growth, led by retail, SME and corporate lending. Surplus foreign-currency deposits and higher repo rates feeding into loan yields could support margins.
• Estimates: Motilal Oswal estimates FY26–28 CAGR of 19.7% for net interest income and 24.1% for net profit. FY27E ROA is 2.07%; ROE is 12.2% in FY27E and 12.5% in FY28E. Price-to-book is 2.2× and 2.0×.
• Price and market cap: Price on 30 October 2026: ₹462; market cap: ₹4.55 lakh crore.
• Risk: CASA declined from 42.3% to 38.2%. If low-cost deposits do not recover, funding costs could delay margin improvement. No target price is given in the subtitles.

2. Titan — Watches and Jewellery

• Growth drivers: Branded jewellery, studded jewellery, store expansion and non-jewellery businesses. Stable gold prices could improve margin visibility.
• Estimates: FY26–29 CAGR of 17% for revenue, 21% for operating profit and 23% for net profit.
• Target and valuation: Target of about ₹6,000, versus ₹4,437 on 30 October 2026—approximately 35% implied upside. FY27E/FY28E P/E: 60.9×/48.7×; ROE: 36.1%/35.1%.
• Risks and caution: Valuation already reflects strong growth expectations. Gold-price volatility, competition and delayed margin recovery could hurt profitability. Monitor studded-jewellery growth and sustainable margins.

3. Adani Ports — Ports and Infrastructure

• Growth levers: Port-capacity additions, infrastructure projects and global acquisitions. The company was said to have ₹125 billion in cash.
• Estimates: Cargo volumes are estimated to grow at 14% CAGR over FY26–28. FY27 capex guidance is ₹15,000–17,000 crore.
• Target and valuation: Target of ₹2,130 versus a quoted price of ₹1,850, implying around 15% upside. FY27E/FY28E P/E: 28.5×/21.5×.
• Market cap: The transcript reports ₹4,263 crore, a figure that may be mistranscribed.
• Risk: Execution delays could defer cargo-volume growth and earnings benefits.

4. Eternal — Food Delivery and Quick Commerce

• Business and growth thesis: The discussion covers Zomato food delivery and Blinkit. Food-delivery order value is targeted to grow more than 20% annually. Customer-acquisition and order-frequency spending is expected to continue, with margins broadly stable.
• Blinkit expansion: Blinkit had 2,751 stores at the end of September 2026. Management targets 3,500+ by March 2027 and about 5,000 by March 2028.
• Estimates: FY26–28 CAGR of about 75% for revenue and 155% for net profit.
• Price, target and valuation: Market cap on 30 October: roughly ₹3.11 lakh crore. Target: ₹420 versus closing price of ₹344, around 22% implied upside. FY27E/FY28E P/E: 390.3×/131.9×; ROE: 2.6%/7.2%.
• Risk: Very high valuation leaves the stock vulnerable if earnings estimates are missed. New stores need to generate orders and contribution.

5. BSE — Stock Exchange and Market Infrastructure

• Growth drivers: Derivatives activity is highlighted as a key driver. Average daily derivatives premium turnover reached a record ₹29,615 crore in Q1, up 96% year on year; F&O turnover was up 85% in October.
• Other factors: A partial rollback of closing-auction norms from 7 December could support activity. The subtitles cite BSE at 30%+ of options premium turnover and a 9% cash-market figure; the precise measure for the latter is unclear. Recurring income also comes from mutual-fund platforms and co-location.
• Risk: Earnings depend on market activity. Slower F&O trading or regulatory changes could reduce volumes and growth.

6. SPR Auto Technologies — Auto Components

• Business and growth thesis: The company is described as a leading manufacturer of pistons, piston rings and engine valves. The subtitles cite a post-acquisition “vehicle on contract” figure of ₹30,000+ (wording unclear) and identify multi-fuel applications as another demand opportunity.
• Estimates: Net-profit growth of 21% CAGR over FY26–29; core ROCE is projected to improve to 20–28%.
• Price, target and valuation: Market cap of about ₹19,700 crore. Price: ₹4,374; target: ₹6,150, around 41% implied upside. FY27E/FY28E P/E: 31.1×/23.1×; ROE: 17%/17.4%.
• Risk: Acquisition-related finance costs were ₹23.4 crore in Q2 and ₹48.6 crore in H1. The transcript cautions that higher EBITDA may not yet be fully converting into PAT.

7. Shaily Engineering Plastics — Plastics and Healthcare-Device Components

• Growth opportunity: Healthcare devices, including semaglutide pens, two new IP-led contracts and reusable auto-injectors. The focus is on converting launches into repeat supply.
• Capacity: Work includes machinery for 25 million additional pens and a potential 75 million pens of annual capacity at the Abu Dhabi facility.
• Estimates: FY26–28 CAGR of 33% for revenue and 48% for net profit. Operating margin could exceed 32% by FY28E.
• Price and market cap: Market cap on 30 October 2026: about ₹14,000 crore; price: ₹3,170.
• Target: A target price is spoken but missing or unintelligible in the subtitles, so implied upside cannot be verified.

8. Arvind — Textiles and Advanced Materials

• Growth drivers: Its integrated textile platform, advanced materials and Phase One of the Varanasi garmenting facility, which could generate ₹250 crore in annual revenue at potential capacity. Dalco GFT integration and capex in advanced materials are also cited.
• Management outlook: Advanced-materials revenue growth of 18% and EBITDA margins of 14–15% in Q3; textile revenue may grow at low double digits.
• Estimates: FY26–28 CAGR of 18% for revenue and 30% for net profit.
• Price, target and valuation: Price on 30 October: ₹491; market cap: about ₹13,800 crore. Target: ₹670, or roughly 37% implied upside. FY27E/FY28E P/E: 22.8×/18.5×; ROE: 12.5%/13.2%.
• Risks: Raw-material, utility and freight costs reduced textile margins by 75 basis points in Q2, while Western demand was cautious. Persistent cost pressure or slower capacity ramp-up could put estimates at risk.

9. Unimech Aerospace — Aerospace, Semiconductors and Manufacturing

• Growth thesis: Growth depends on moving aircraft-tooling work and first-article inspections into approved serial production. A 20-month semiconductor program with global OEMs is expected to drive a revenue step-up. Other initiatives include a Saudi JV, a special-process cell and expanded aerospace capabilities.
• Estimates: FY26–28 CAGR of 75% for revenue and 69% for net profit; operating margin is projected above 38%.
• Price, target and valuation: Market cap: ₹8,300 crore; price: ₹1,579 on 30 October 2026. Target: ₹2,038, around 35% implied upside. FY27E/FY28E P/E: 61.5×/45.6×; ROE: 15%/16.9%.
• Risk: Order conversion. Of an ₹855 crore order book/program value, only ₹266 crore is described as confirmed. Delays in qualification or serial production could defer the remaining LTA/Letter of Award programs.

10. Symbiotech Pharmalab — Biotech CDMO and Pharmaceuticals

• Business and growth thesis: 67% of FY26 revenue came from exports. The subtitles cite capex of “$16.7 billion by FY27” to commercialize new manufacturing capacity; the currency or unit may be mistranscribed.
• Pipeline and contracts: The company filed in the US for a first double-chamber vial product in complex injectables, with a second filing expected in Q4 FY27. It has five-year take-or-pay agreements for insulin and ten-year agreements for alternative proteins in its biotech CDMO business.
• Estimates: FY26–29 CAGR of 33% for revenue, 33% for EBITDA and 37% for PAT; ROE is expected to reach 17%. A separate ROE projection is 10.4% in FY27E and 11.6% in FY28E.
• Price, target and valuation: Price: ₹1,246 on 30 October; target: ₹1,430, about 15% implied upside. The reported market cap of “$79 billion” appears potentially mistranscribed.
• Risk: New businesses incurred ₹23 crore of operating expenses and ₹11 crore of depreciation in Q1 FY27, before revenue had begun.

Overall Takeaways

• The ideas span banking, jewellery, ports, digital commerce, exchange infrastructure, auto components, healthcare plastics, textiles, aerospace and biotech manufacturing.
• The video repeatedly emphasizes execution: converting capacity, contracts, store expansion and order books into revenue, margins and profit.
• Several picks have high growth projections and elevated valuation multiples. Missed earnings, cost pressures, regulation, market slowdowns or execution delays could weigh on share prices.
• No explicit tickers, ETFs, bonds, commodities or crypto assets are mentioned. The instruments discussed are individual company equities and valuation measures such as P/E, price-to-book, ROE and ROCE.

Disclaimer: Investments in securities markets are subject to market risks; investors should read all related documents carefully before investing.

Presenters and sources: No individual presenter is identified in the subtitles. The stock ideas and estimates are attributed to Motilal Oswal’s Fundamental Research Team / Research Desk.